ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / KRSA / news
AAPG (45) OMER (41) NKTR (20) DMRA (35) ⌘ Pro Terminal →

Why KRSA Stock surged +5.04% Today — RQD Quant Desk Flash

$31.66 +5.04% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $31.89

Korsana Biosciences Inc. (KRSA) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.37B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KRSA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KRSA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Korsana Biosciences Inc. (NASDAQ: KRSA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $31.66 (+5.04% 1D, market cap $1.37B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, KRSA ranks #501 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KRSA compare to AAPG and OMER in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KRSA carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -5.7%. By comparison, AAPG (Ascentage Pharma Group International American Depository Shares) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $1.35B) and OMER (Omeros Corporation) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B). Among the 5-stock peer group, KRSA leads on earnings multiple (N/A) while KRSA leads on capital efficiency (-5.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KRSA?
▼

Per KRSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001755237), Korsana Biosciences Inc. generated $2.1M in revenue (+3.7% YoY), -$3.5M in net income, and -$3.3M in free cash flow against $10.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $31.89 (+0.72%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510038
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D-
Cash (9)Whales (9)SEC (8)Macro (9)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
$62 Bull$29 Base$22 Bear
📬 FREE KRSA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KRSA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY KRSA SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
30
Grade E$31.66-2% Next Q
Q2 (-2Q)
33
Grade E$31.03-3.1% Next Q
Q3 (-1Q)
35
Grade E$30.07+5.3% Next Q
Current
38
Grade D-$31.66-7.8% Hist 90D α
Trajectory: E (30) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KRSA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KRSA currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($31.20) and Max Pain ($33.24) forces dealer call-delta covering toward $62.33.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KRSA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KRSA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 38%NO 62%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why KRSA Stock surged +5.04% Today — RQD Quant Desk Flash

Korsana Biosciences Inc. (KRSA) surged +5.04% to $31.66, trading at 47% of its 52-week range ($7.19 – $59.36). Stretched risk/reward at current multiples (-6% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 47% of its 52-week range ($7.19 – $59.36) with RSI-14 at 45.7 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $31.66 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live KRSA Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KRSA)

  • ✓Walkthrough of KRSA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KRSA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +38.74%📐 HORIZONTAL RANGE
2026-11-03O $30.22H $31.66L $30.14C $31.66VOL 104.2K
RES: $43.95SUP: $19.33SMA50: $31.20SMA200: $22.16
$38.86$32.25$25.64$19.03$12.42RES $43.95SUP $19.33$31.662026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KRSA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KRSA Butterfly Map → + Track KRSA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +3.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KRSA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KRSA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KRSA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KRSA)

Health Care Rank #501 of 1015 ⚔️ AAPG vs KRSA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KRSA vs. AAPG, OMER, NKTR, DMRA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Korsana Biosciences Inc. (KRSA) ranks #501 by composite RQD confidence (38/100, grade D-) and #310 by equity capitalization ($1.37B). Within this direct 5-issuer industry benchmark cohort, KRSA leads on earnings valuation at N/A trailing P/E, while KRSA leads on capital efficiency and profitability with -5.7% ROIC and — gross margin. AAPG currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with KRSA at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KRSA ACTIVE
Korsana Biosciences Inc.
D- 38/100 — — -5.7% +5.04% $1.37B Benchmark Subject
AAPG
Ascentage Pharma Group International American Depository Shares
D 45/100 — — — -6.20% $1.35B /aapg-vs-krsa →
OMER
Omeros Corporation
D- 41/100 — — -35.0% -3.31% $1.33B /omer-vs-krsa →
NKTR
Nektar Therapeutics
E 20/100 — 96.0% -35.0% -4.94% $1.33B /nktr-vs-krsa →
DMRA
Damora Therapeutics Inc.
D- 35/100 — — -35.0% +0.51% $1.33B /dmra-vs-krsa →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001755237 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Korsana Biosciences Inc. (KRSA) reported GAAP revenue of $2.1M (+3.7% vs. FY2024 revenue of $2.0M , and -94.3% cumulative change since FY2023) , GAAP net income of -$3.5M, operating cash flow of -$3.3M, and free cash flow of -$3.3M (+23.5% YoY). On the balance sheet, KRSA closed FY2025 with $10.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.1M -$3.5M -$3.3M -$3.3M $10.0M —
FY2024 (FY) 2024-12-31 $2.0M -$3.1M -$4.3M -$4.3M $9.6M —
FY2023 (FY) 2023-12-31 $36.3M -$5.3M -$21.2M -$21.2M — —

3. KRSA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KRSA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Korsana Biosciences Inc. (NASDAQ: KRSA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $31.66 (+5.04% 1D, market cap $1.37B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, KRSA ranks #501 in composite RQD confidence.

How does KRSA compare to AAPG and OMER in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KRSA carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -5.7%. By comparison, AAPG (Ascentage Pharma Group International American Depository Shares) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $1.35B) and OMER (Omeros Corporation) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B). Among the 5-stock peer group, KRSA leads on earnings multiple (N/A) while KRSA leads on capital efficiency (-5.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KRSA?

Per KRSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001755237), Korsana Biosciences Inc. generated $2.1M in revenue (+3.7% YoY), -$3.5M in net income, and -$3.3M in free cash flow against $10.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KRSA trading relative to its 50-day, 200-day, and 52-week technical levels?

KRSA last traded at $31.66 (+5.04% on volume of 197,556 shares), positioning the stock +1.47% above its 50-day simple moving average ($31.20) and +42.87% above its 200-day simple moving average ($22.16). Across its 52-week range of $7.19 to $59.36, KRSA sits at the 46.9% percentile with a 14-day RSI of 45.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($27.70 to $35.62).

Direct Sub-Reports: KRSA RQD Cockpit KRSA 12M Forecast KRSA Earnings & Move KRSA Dividends & DRIP KRSA Insiders & 13F KRSA Whale Options KRSA Profit Sankey KRSA News & Why
ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ SEC XBRL & RQD VERIFIED

KRSA — Korsana Biosciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Korsana Biosciences Inc. (KRSA) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $31.66 (+5.04% 1D, market capitalization $1.37B).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -5.7%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -0.24%.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Korsana Biosciences Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue of $2.1M for FY 2025 is shown in the SEC financials, but the sources do not identify the revenue streams behind it.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Korsana Biosciences Inc. (KRSA) reported $2.1M in annual revenue (up from $2.0M in FY2024, +3.7% YoY) and -$3.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($36.3M revenue, -$5.3M net income) through FY2025, KRSA scaled operating cash flow to -$3.3M and free cash flow to -$3.3M, backed by $10.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -0.24% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $7.19 – $59.36 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), KRSA carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can KRSA sustain or expand its -60.0% operating margin and -5.7% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.1M and free cash flow of -$3.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is KRSA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KRSA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Korsana Biosciences Inc. (KRSA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KRSA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KRSA Bull vs. Bear Conversation Board — What's Your Call at $31.66?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KRSA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KRSA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $36.77 (+22.0%)
📌 Pinned Debate

Wedbush initiated coverage with an outperform rating, the only positive catalyst in the news feed.

Picked up a starter position in KRSA in my $100K Virtual Cash book at $30.14. Wedbush initiated coverage with an outperform rating, the only positive catalyst in the news feed.. Trading inside a $7.19–$59.36 52-week range with -0.24% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@QuantViper Agree on the RQD 38/100 quality, though with 1.0 beta I'm scaling in with half-size at $30.14 and keeping dry powder in case we test $28.03.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $25.02 (-17.0%)
Spot @ $30.14

Negative ROIC of -5.7%, a -0.24% FCF yield, and an insider score of 3/20 indicate weak cash generation and limited insider conviction.

Negative ROIC of -5.7%, a -0.24% FCF yield, and an insider score of 3/20 indicate weak cash generation and limited insider conviction.. Look at the math on KRSA: paying current EV/EBITDA multiples for -5.7% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $26.52 before getting long.

LIVE TAPE